ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

POLX Polarean Imaging Plc

4.30
0.00 (0.00%)
Last Updated: 08:00:04
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.30 4.20 4.40 4.30 4.30 4.30 694,474 08:00:04
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 1.03M -13.91M -0.0644 -0.67 9.28M

Polarean Imaging PLC Extension of Warrants (4060B)

02/06/2023 7:00am

UK Regulatory


Polarean Imaging (LSE:POLX)
Historical Stock Chart


From Mar 2023 to Mar 2024

Click Here for more Polarean Imaging Charts.

TIDMPOLX

RNS Number : 4060B

Polarean Imaging PLC

02 June 2023

Polarean Imaging Plc

("Polarean" or the "Company")

Extension of Warrants

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, announces that the Board has approved the extension of the expiry date of 852,822 warrants over ordinary shares in the Company (the "Warrants"), held by Mr. Kenneth West, Chairman of the Company, to 31 July 2023 from their current expiry date of 2 June 2023. The Warrants were issued on 3 June 2013 to a consulting group for which Mr. West was a partner and subsequently assigned to Mr. West. All other terms of the Warrants remain unchanged.

The extension of the expiry date for the Warrants amounts to a related party transaction within the meaning of the AIM Rules for Companies. The Directors who are independent of the related party transaction (being all the Directors of the Company other than Mr. Kenneth West) having consulted with Stifel, the Company's nominated adviser, consider this proposed extension of the expiry date to be fair and reasonable insofar as the shareholders of the Company are concerned.

Mr. Kenneth West holds a total of 2,801,084 warrants over ordinary shares of the Company. In addition, Kenneth also holds options for 2,263,218 shares and 475,594 ordinary shares.

Enquiries:

 
  Polarean Imaging plc                                                  www.polarean.com / www.polarean-ir.com 
  Richard Hullihen, Chief Executive                                                            Via Walbrook PR 
   Officer 
  Kenneth West, Chairman 
 
  Stifel Nicolaus Europe Limited (NOMAD and 
   Sole Corporate Broker)                                                                  +44 (0)20 7710 7600 
  Nicholas Moore / Samira Essebiyea / Kate Hanshaw 
   (Healthcare 
   Investment Banking) 
  Nick Adams / Nick Harland (Corporate Broking) 
 
  Walbrook PR                                              Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
  Anna Dunphy / Phillip Marriage                                            Mob: +44 (0)7876 741 001 / +44 (0) 
                                                                                                  7867 984 082 
 
 
 

About Polarean ( www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEW(TM) (Xenon Xe(129) hyperpolarised). Xe(129) MRI is also currently being studied for visualisation and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUAVVRORUNRAR

(END) Dow Jones Newswires

June 02, 2023 02:00 ET (06:00 GMT)

1 Year Polarean Imaging Chart

1 Year Polarean Imaging Chart

1 Month Polarean Imaging Chart

1 Month Polarean Imaging Chart

Your Recent History

Delayed Upgrade Clock